Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

AbstractThe increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune ‐related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been large ly ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases.Key pointsThis review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor ‐related ocular adverse events.

Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Xiaowei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang, Li Zhang Tags: CLINICAL GUIDELINE Source Type: research